Cat. No. 2999
Chemical Name: 4-[4-(4-Fluorophenyl)-1-(3-phenylpr
Biological ActivitySelective p38α and p38β inhibitor (IC50 values are 1 and 11 μM respectively) that displays no activity at p38γ, p38δ and a range of other kinases. Potently inhibits TNF-α and IL-1β release (IC50 values are 3 and 11 nM respectively) and suppresses HIV-1 replication in T cells in vitro. Displays cardioprotective and anti-inflammatory activity in vivo. Orally active.
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
Certificate of Analysis / Product Datasheet / Safety Data Sheet
Muthumani et al (2004) Suppresssion of HIV-1 viral replication and cellular pathogenesis by a novel p38/JNK kinase inhibitor. AIDS 18 739. PMID: 15075508.
See et al (2004) p38 mitogen activated protein kinase inhibition improves cardiac function and attenuates left ventricular remodeling fowllowing myocardial infarction in the rat. J.Am.Coll.Cardiol. 44 1679. PMID: 15489104.
Wadsworth et al (1999) RWJ 67657, a potent, orally active inhibitor of p38 mitogen-activated protein kinase. J.Pharm.Exp.Ther. 291 680.
If you know of a relevant reference for this product please let us know.
Citations are publications that use Tocris products.
Do you know of a great paper that uses RWJ 67657 from Tocris? If so please let us know.
View Related Products by Target
View Related Products by Product Action
Keywords: RWJ 67657, supplier, Potent, selective, p38α, p38alpha, p38β, p38beta, inhibitors, inhibits, MAPK, Signaling, Signalling, Mitogen-Activated, Protein, Kinases, RWJ67657, Tocris Bioscience, p38 MAPK Inhibitor products
Find multiple products by catalog number
New Products in this Area
Selective p38α/β inhibitor; orally bioavailableAX 15836
Potent and selective ERK5 inhibitor
Follow Tocris on LinkedIn
Visit our LinkedIn page for the latest Tocris news, events and updates.